If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?Halozyme Therapeutics' Business In-DepthWith that in mind, let's take a look at Halozyme Therapeutics' main business drivers.San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.The company’s ENHANZE drug delivery technology helps in developing the SC formulation of drugs. Several companies, including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others, are using this technology for developing the SC formulation of their currently marketed drugs. It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform.Halozyme now has eight marketed partnered drugs based on this technology.Halozyme currently earns royalties on sales of various commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).The company’s commercial portfolio of products include — Hylenex Recombinant and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from Xyosted have been driving top-line growth.Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. The company generated total revenues of $1.02 billion in 2024, up 22% year over year. This marked the first time that the company has managed to breach the $1 billion mark in total revenues. Bottom LineAnyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Halozyme Therapeutics, ten years ago, you're likely feeling pretty good about your investment today.A $1000 investment made in January 2016 would be worth $8,334.09, or a gain of 733.41%, as of January 30, 2026, according to our calculations. This return excludes dividends but includes price appreciation.Compare this to the S&P 500's rally of 259.18% and gold's return of 363.68% over the same time frame.Analysts are anticipating more upside for HALO.Halozyme has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments, which are driving the company's top line. Robust demand for the subcutaneous formulation of J&J's Darzalex and Roche's Phesgo is boosting royalties and the top line. The momentum is likely to continue in 2026. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan, which utilize ENHANZE technology, are now facing biosimilar competition, resulting in potential decreased revenues from royalties. High dependence on partners for revenues in the form of royalties and collaborative agreements is a concern. Any deal termination will hurt the stock negatively.The stock is up 8.97% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2025. The consensus estimate has moved up as well.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks